ArticleNature communications2021
Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis.
Abstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Chronic Gastric Ulceration Due to Cytomegalovirus in Immunocompetent Adults - A Case Report and Systematic Review.Reviews in medical virology · 2026Pooled it
- Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart.Journal for immunotherapy of cancer · 2025Pooled it
- Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.International journal of molecular sciences · 2021Trial
- Macrophage-CD8medRxiv : the preprint server for health sciences · 2026Article
- Expanding the supply of human leukocytes for research by harvesting cell concentrates from Trima Accel tubing sets.Scientific reports · 2026Article
- Across the Social Network of the Gut: Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity.International journal of molecular sciences · 2026Review
- From mechanisms to practice: risk management and multidisciplinary decision-making for systemic treatment-related liver injury in HBV-associated hepatocellular carcinoma.Frontiers in pharmacology · 2026Review
- The role of metabolites in the causal effect of immune cell phenotypes on immunotherapy toxicity risk.Discover oncology · 2025Article
- Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab.Oncoimmunology · 2025Article
- The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Review
- Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist.Journal of neurology, neurosurgery, and psychiatry · 2025Review
- Extracorporeal photopheresis for pembrolizumab-induced dermatitis: a case report.Skin health and disease · 2025Article
- Distinct Immunological Landscapes of HCMV-Specific T Cells in Bone Marrow and Peripheral Blood.Pathogens (Basel, Switzerland) · 2025Article
- Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention.Nature reviews. Clinical oncology · 2025Review
- Platelet apheresis with additive solution and plasma rinseback affects the cellular composition of LRS chamber products.Scientific reports · 2025Article
- Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma.EJNMMI research · 2025Article
- AND-gated protease-activated nanosensors for programmable detection of anti-tumour immunity.Nature nanotechnology · 2025Article
- Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management.Nature reviews. Gastroenterology & hepatology · 2025Review
- CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients.Cancer immunology, immunotherapy : CII · 2025Article
- Recent Updates on the Pathogenesis of Inflammatory Myopathies.Current rheumatology reports · 2024Review
Corrections and comments
- Commented on by
Authors and funding
24 authors.
James A HutchinsonDepartment of Surgery, University Hospital Regensburg, Regensburg, Germany. james.hutchinson@ukr.de.ORCID http://orcid.org/0000-0002-1199-4210
Katharina KronenbergDepartment of Surgery, University Hospital Regensburg, Regensburg, Germany.
Paloma RiquelmeDepartment of Surgery, University Hospital Regensburg, Regensburg, Germany.
Jürgen J WenzelInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0001-8422-6581
Gunther GlehrInstitute of Functional Genomics and Statistical Bioinformatics, University of Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0002-1495-9162
Hannah-Lou SchillingDepartment of Surgery, University Hospital Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0002-5506-3506
Florian ZemanCenter for Clinical Studies, University Hospital Regensburg, Regensburg, Germany.
Katja EvertInstitute of Pathology, University Hospital Regensburg, Regensburg, Germany.
Martin SchmiedelDepartment of Nuclear Medicine, University Hospital Regensburg, Regensburg, Germany.
Marion MicklerDepartment of Dermatology, University Hospital Regensburg, Regensburg, Germany.
Konstantin DrexlerDepartment of Dermatology, University Hospital Regensburg, Regensburg, Germany.
Florian BittererDepartment of Surgery, University Hospital Regensburg, Regensburg, Germany.
Laura CorderoDepartment of Surgery, University Hospital Regensburg, Regensburg, Germany.
Lukas BeyerInstitute of Radiology, University Hospital Regensburg, Regensburg, Germany.
Christian BachDepartment of Medicine V, University Hospital Erlangen, Erlangen, Germany.
Josef KoestlerInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
Ralph BurkhardtInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
Hans J SchlittDepartment of Surgery, University Hospital Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0002-3874-0296
Dirk HellwigDepartment of Nuclear Medicine, University Hospital Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0002-3056-0143
Jens M WernerDepartment of Surgery, University Hospital Regensburg, Regensburg, Germany.
Rainer SpangInstitute of Functional Genomics and Statistical Bioinformatics, University of Regensburg, Regensburg, Germany.
Barbara SchmidtInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0003-0059-0349
Edward K GeisslerDepartment of Surgery, University Hospital Regensburg, Regensburg, Germany.
Sebastian HaferkampDepartment of Dermatology, University Hospital Regensburg, Regensburg, Germany.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of advanced melanoma with combined PD-1/CTLA-4 blockade commonly causes serious immune-mediated complications. Here, we identify a subset of patients predisposed to immune checkpoint blockade-related hepatitis who are distinguished by chronic expansion of effector memory CD4
Indexed as
Antiviral AgentsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCTLA-4 AntigenCytomegalovirusCytomegalovirus InfectionsHepatitis AHumansImmune Checkpoint InhibitorsImmunologic MemoryMelanomaProgrammed Cell Death 1 ReceptorValganciclovirViral LoadAntiviral AgentsCTLA-4 AntigenCTLA4 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorValganciclovir
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.